Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease

47Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Inflammatory cytokines are important predictors of cardiovascular mortality especially in patients with chronic kidney disease. Here we explored the relationship of anemia and epoetin treatment to inflammatory cytokine levels in patients with chronic kidney disease. One hundred non-dialysis patients with chronic kidney disease over 18 years of age were evenly split into anemic and non-anemic cohorts. Of the 50 anemic patients, 23 were receiving erythropoiesis stimulating agents treatments. Levels of tumor necrosis factor (TNF)-α were found to be significantly higher and serum albumin was significantly lower with trends towards higher interleukin (IL)-6 and IL-8 in anemic compared to non-anemic patients. Further analysis by multiple logistic regression found that anemic patients treated with erythropoiesis stimulating agents had significantly higher odds for the upper two quartiles for IL-6, IL-8 and TNF-α compared to non-anemic patients. Our study found that the anemia of chronic kidney disease was associated with up regulation of TNF-α, and possibly IL-6 and IL-8 along with increased levels of these proinflammatory cytokines in patients treated with epoetin. © 2008 International Society of Nephrology.

Cite

CITATION STYLE

APA

Keithi-Reddy, S. R., Addabbo, F., Patel, T. V., Mittal, B. V., Goligorsky, M. S., & Singh, A. K. (2008). Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney International, 74(6), 782–790. https://doi.org/10.1038/ki.2008.245

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free